Roche buys Genentech for $46.8 billion

Swiss drug maker Roche has struck a deal with shareholders to purchase biotech group Genentech for $46.8 billion (SFr54.11 billion).

This content was published on March 12, 2009 - 09:12

Board members at Genentech, a California-based company, agreed to sell Roche all outstanding shares for $95 each in cash. It is one of the most expensive deals in the history of the Swiss economy.

The deal ends a drawn-out battle that began last year and turned hostile for several months after Roche's initial bid was rejected. The financial crisis then struck, casting doubts about the takeover.

Roche later increased its offer after meeting with Genentech investors. The new deal gives the Basel-based firm 44 per cent of Genentech that it did not already control and creates a sales force of about 3,000 people.

Roche will now control Genentech's popular cancer drugs Avastin and Herceptin. Executives estimate annual revenues from the two companies should be around $17 billion.

Articles in this story

In compliance with the JTI standards

In compliance with the JTI standards

More: SWI certified by the Journalism Trust Initiative

You can find an overview of ongoing debates with our journalists here. Please join us!

If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at

Sort by

Change your password

Do you really want to delete your profile?

Your subscription could not be saved. Please try again.
Almost finished... We need to confirm your email address. To complete the subscription process, please click the link in the email we just sent you.

Discover our weekly must-reads for free!

Sign up to get our top stories straight into your mailbox.

The SBC Privacy Policy provides additional information on how your data is processed.